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SUMMARY: Mixed endocrine-exocrine tumors of the gut are a heterogeneous group of neoplasms with uncertain histogenesis
showing different morphologic and clinical features. The aim of this work is to clarify the histogenesis of these tumors by studying
the genetic profile of both the endocrine and exocrine components. We performed an allelotyping analysis of five mixed
endocrine-exocrine tumors (two gastric and three colonic) and one rectal collision tumor, using 35 polymorphic microsatellite
markers covering a total of six chromosomes, including 3, 5q, 6, 11, 17, and 18. The loss of heterozygosity (LOH) analysis showed
concurrent losses of the same allele in both the endocrine and exocrine components in all of the five mixed tumors composed
by a poorly differentiated endocrine carcinoma or a well differentiated endocrine carcinoma associated with adenocarcinoma or
adenoma. Among these tumors an identical LOH pattern was frequently found on chromosomes 17p, 18q, and 5q. Additional
allelic losses restricted to the poorly differentiated endocrine carcinoma were often observed. On the contrary, in the only collision
tumor composed by a well differentiated endocrine carcinoma associated with adenocarcinoma, completely different allelotypes
between the two components were detected. These findings confirm a close genetic relationship between the two distinct
histologic components within mixed endocrine-exocrine tumors, supporting the hypothesis that a monoclonal mechanism of
tumorigenesis is the most frequent genetic event in mixed exocrine-endocrine tumors. The clonal divergence observed in the only
collision tumor, composed by a well differentiated endocrine carcinoma associated with an adenocarcinoma, confirms the
existence of double tumors growing next to each other coincidentally but showing different histogenesis and different
tumorigenetic pathways. (Lab Invest 2003, 83:963–971).
M ixed endocrine-exocrine tumors of the gut con-stitute a heterogeneous group of rare neo-
plasms, which includes different histopathologic and
prognostic classes. Microscopically, they consist of
an adenomatous and/or carcinomatous component
associated either with a well differentiated endocrine
tumor (WDET) or with a poorly differentiated endocrine
carcinoma (PDEC). The endocrine component repre-
sents at least one-third to half of the tumor tissue,
either intimately and diffusely admixed with the exo-
crine component (combined tumors) or occurring
mainly as separate areas in the same neoplasm (com-
posite tumors) (Capella et al, 2000). Endocrine-
exocrine collision tumors are composed of two topo-
graphically clearly separated components and by
definition are not included in the category of mixed
tumors.
According to such morphologic classification, two
opposite hypotheses have been proposed regarding
the histogenesis of these biphenotypic tumors. One
model suggests that the exocrine and endocrine com-
ponents expand from two distinct precursors through
different tumorigenetic pathways resulting in double
tumors (named “collision-type tumors”) that exist next
to each other coincidentally. In this view, the endo-
crine tumor with adjacent satellite adenocarcinoma
was suggested to exert paracrine effects on the sur-
rounding glandular epithelial cells (Peison and Be-
nisch, 1983; Yamashita and Flinner, 1985). However,
there are no molecular studies supporting this model.
The other hypothesis suggests a monoclonal origin
of the two components from a pluripotent epithelial
stem cell undergoing an anaplastic transformation
with a bidirectional differentiation. In agreement with
this model, two different studies have recently re-
ported a microallelotyping analysis of seven colorectal
PDECs (Vortmeyer et al, 1997) and of eight gastric
PDECs (Kim et al, 2002) associated with adenomas or
adenocarcinomas. In both studies, using a genome-
wide approach (Kim et al, 2002) or a loss of heterozy-
gosity (LOH) analysis restricted to APC, DCC, and p53
loci (Vortmeyer et al, 1997), a close genetic relation-
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ship was observed between the two components,
regardless of the typology of the mixed tumors ana-
lyzed. Because additional genetic alterations re-
stricted to PDEC have been detected, it was specu-
lated that a mixed exocrine-endocrine tumor evolves
from a single epithelial precursor following an exocrine
to endocrine cell-type sequence and not vice versa
(Kim et al, 2002). Moreover, it was emphasized that
the differentiation into PDEC may occur at a relatively
early stage of carcinogenesis as demonstrated by the
existence of mixed PDEC with a minimal exocrine
component represented by areas of high grade dys-
plasia or adenoma. Interestingly, because specimens
of pure colorectal PDEC without an exocrine compo-
nent exhibit genetic changes of the adenoma-
adenocarcinoma sequence (including APC, DCC, and
p53 LOH), it was speculated that both mixed and pure
PDECs share histogenesis and pathogenetic mecha-
nisms with adenocarcinoma (Vortmeyer et al, 1997).
With regard to WDETs, a few molecular studies
have also been performed to elucidate the potential
role of the tumor suppressor genes APC, DCC, and
p53 (Ramnani et al, 1999; Vortmeyer et al, 1997). Even
though the importance of these genes remains to be
clarified, such preliminary findings suggest that
WDETs do not share cancerogenetic pathways with
adenocarcinomas and may represent genetically dis-
tinct neoplasms.
In the present study, we performed an allelotyping
analysis of one rectal collision tumor formed by a well
differentiated endocrine carcinoma (WDEC) and an ad-
enocarcinoma and of five mixed PDECs/WDEC-
adenocarcinomas or adenomas (two of the stomach and
three of the colon). We used 35 polymorphic microsat-
ellite markers covering a series of chromosomal regions
considered to be critical in both gastrointestinal exocrine
and endocrine tumorigenesis. Some of these genetic loci
are known to harbor tumor suppressor genes, including
APC (5q21), TP53 (17p13.2), DCC and SMAD4 (18q21),
ATM (11q22.3), MEN1 (11q13), VHL (3p25–26), FHIT
(3p14.2), and SEN6 (6q27). The aim of this work was to
analyze the genetic relationships between the microdis-
sected endocrine and exocrine components of the
mixed tumors and the collision tumor defining the clonal-
ity and the timing of the genetic events during the
progression of these neoplasms.
Results
One collision neoplasm, five mixed endocrine-exocrine
tumors, and one adenocarcinoma from six patients were
microdissected. A total of 14 tumor foci (including two
microspecimens from the endocrine and exocrine com-
ponents of each mixed or collision tumor, one mi-
crospecimen from a synchronous gastric adenocarci-
noma, and one microspecimen from high grade
dysplasia focus adjacent to the gastric mixed tumor of
Patient 1) were analyzed for LOH at 35 polymorphic
microsatellite markers covering chromosomes 3, 5q, 6,
11, 17, and 18 (Table 1). The detailed results of the
microallelotyping analysis are shown in Table 2.
Regardless of the primary site, LOH at TP53 locus
and/or an immunohistochemical p53 protein accumu-
lation was observed in the endocrine components of
all of the five mixed tumors examined (Cases 1 to 5 in
Tables 2 and 3). In these cases, the adenocarcinomas
associated with the endocrine components invariably
shared an identical allelic loss at TP53 marker and/or
an immunohistochemical p53 accumulation (Cases 1
to 3 and 5). In the adenoma of the mixed tumor 4
(Table 2), a condition of borderline allelic imbalance at
TP53 locus was observed for the same allele lost in the
PDEC component. These findings indicating a condi-
tion of intratumor heterogeneity for TP53 LOH were
Table 1. Chromosomal Locations of the Microsatellite
Marker Set Used for the Allelotyping Analysis
Chromosome
arm Locus Cytogenetic band
Known or putative
genes contained
3p 1038 3p26.1-p25.2 VHL (3p26-p25)
1581 3p21.2-p14.2
1606 3p21.31-p14.2 FHIT (3p14.2)
1295 3p21.31-p14.2 ]
1300 3p21-p14.2
3q 1614 3q25.2-q26.2
1580 3q27-q28
5q APC 5q21-q22 APC (5q21)
6p 1610 6p21-p22
6q 268 6q21-q22
261 6q21-q22
1639 6q21-q22
441 6q25
415 6q25
193 6q27 ] SEN6 (6q27)297 6q27
11p 922 11p15.4
1318 11p15.4
4088 11p15.4
4181 11p15.3
11q PYGM 11q13 ] MEN1 (11q13)INT2 11q13
917 11q14-q22 ATM (11q22.3)
1339 11q21-q22
2000 11q22 ]927 11q21-q22
1347 11q21-q22
17p TP53 17p13.2 TP53 (17p13.2)
17q 787 17q21-q22
928 17q23-q24
18p 63 18p11
452 18p11
18q 363 18q21 ] DCC/SMAD4474 18q21 (18q21)
70 18q23
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consistent with a focal immunohistochemical p53 pro-
tein accumulation observed in the colorectal adenoma
(Table 3).
In addition to TP53 LOH or p53 immunohistochem-
ical abnormalities, D17S928 LOH was also observed
in both the components of the tumors 1, 2, and 5.
Interestingly, the high grade dysplasia adjacent to the
gastric mixed tumor of Patient 1 exhibited loss of the
same allele at TP53 and D17S928 locus as the two
components of the mixed tumor. On the contrary, the
synchronous adenocarcinoma of the same patient
showed an allelic retention at the same locus (Fig. 1).
Additional chromosomal regions with concurrent
allelic losses in the endocrine and exocrine compo-
Table 2. Results of the Microallelotyping Analysis
Patient No. 1 2 3 4 5 6
Hystological
type Adc D MuAdc PDEC Adc PDEC MuAdc WDEC Ad PDEC Adc PDEC Adc WDEC
Chromosome
arm and
markers
1038 — — — —   — — ▫ ▫ nd ▫ ▫ 
1581 ▫ ▫ ▫ ▫ Œ Œ ▫ Œ ▫ ▫ ▫ ▫ ▫ 
3p 1606 ▫ ▫ ▫ ▫ ▫ Œ — — ▫ ▫ — — nd nd
1295 ▫ ▫ ▫ ▫ — — nd nd — — nd nd — —
1300 — — — — nd nd ▫ Œ ▫ ▫ nd nd — —
3q 1614 nd nd nd nd — — nd  — — — — ▫ ▫1580 ▫ ▫ ▫ ▫ ▫ ▫ — — nd nd nd nd — —
5q APC  ▫ ▫ Œ ▫ Œ     Œ Œ  ▫
6p 1610 — — — — ▫ ▫ — — nd nd nd nd nd nd
268  ▫ ▫ ▫ ▫ ▫ Œ Œ ▫ ▫ ▫ ▫ — —
261 Œ ▫ ▫ ▫ ▫ Œ — — ▫ ▫ ▫ ▫ ▫ ▫
1639 Œ ▫ ▫ ▫ ▫  ▫ ▫ ▫ ▫ ▫ ▫ — —
6q 441 Œ Œ ▫ ▫ ▫ Œ ▫  ▫ ▫ ▫ ▫ ▫ ▫
415   ▫ ▫ ▫ Œ ▫ ▫ — — ▫ ▫ ▫ ▫
193 Œ Œ ▫ ▫ ▫ Œ ▫ ▫ — — — — ▫ ▫
297 — — — — — — — — ▫ ▫ — — ▫ ▫
922   ▫ ▫ ▫ ▫ ▫ ▫ — — Œ Œ ▫ ▫
11p 1318    ▫ ▫ Œ ▫ ▫ ▫   ▫ 4088 Œ Œ ▫ ▫ nd nd — — — — — — — —
4181 Œ Œ ▫ ▫ — — nd nd ▫ ▫ nd nd nd nd
PYGM   ▫ ▫ nd nd ▫ ▫ ▫ ▫ Œ  ▫ ▫
INT2   ▫ ▫   ▫ ▫ ▫ ▫ ▫  ▫ ▫
917 — — — — Œ Œ ▫ ▫ — — Œ  ▫ Œ
11q 1339 Œ Œ Œ ▫ — — — — — — Œ  ▫ 
2000    ▫ nd nd nd nd nd nd nd nd — —
927 Œ Œ Œ ▫   nd nd ▫ ▫ nd nd nd nd
1347   ▫ ▫   — — — — — — ▫ Œ
17p TP53 ▫    Œ Œ   * Œ — —  ▫
17q 787 — — — — — — ▫ ▫ ▫ ▫ — — nd nd928 ▫      nd nd — —   Œ ▫
18p 63 nd nd nd nd — — nd nd ▫ ▫ — — — —452 — — — — ▫ ▫ ▫ ▫ nd nd nd nd ▫ ▫
363  Œ Œ Œ — — Œ Œ Œ Œ ▫ ▫ — —
18q 474 — — — — ▫ Œ — — — — ▫ ▫ Œ ▫
70 nd nd nd nd ▫ ▫ — — ▫ ▫ ▫ ▫  ▫
Adc, adenocarcinoma; D, displasia; MuAdc, mucinous Adc associated with the poorly differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine
carcinoma; Ad, adenoma; WDEC, well-differentiated endocrine carcinoma; Œ, LOH of the larger allele; , LOH of the smaller allele; ▫, allelic retention; —, not
informative; nd, not determined; *, borderline allelic imbalance of the larger allele.
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nents were also observed. In particular, LOH at 18q
markers (including D18S363 and D18S474) was de-
tected in all but one endocrine components of mixed
cases examined (Cases 1 to 4), and the same allelic
losses were exhibited by the associated adenoma or
adenocarcinoma of one gastric (Case 1) and two
colorectal mixed tumors (Cases 3 and 4). Analogously,
a concurrent loss of the same allele in both compo-
nents was observed in Case 2 at 11q and 3p loci and
in Case 3 at D6S268, respectively. Interestingly, in all
colorectal mixed tumors (Cases 3 to 5), the loss of the
larger or the smaller allele at APC marker was shared
by the associated adenoma or adenocarcinoma.
It is worth noting that in all of the common LOH
regions reported above, a condition of stronger ge-
netic homogeneity (see “Material and Methods” sec-
tion) was invariably observed in the endocrine than in
the exocrine component.
The PDEC and WDEC of three mixed tumors (Pa-
tients 1 to 3) exhibited further LOH regions in addition
to those shared with the exocrine components (Table
2). These allelic losses involved 11p, 6q, and 18q arms
(Case 2), APC marker (Cases 1 and 2), and chromo-
some 3 (Case 3).
No additional LOH regions restricted to the exocrine
component were found, with the exception of LOH at
11 chromosome markers (D11S1339, D11S2000,
D11S927, and D11S1318) observed in only the ade-
nocarcinoma of the mixed tumor of Patient 1. In one
specimen (Case 5), allelic loss of the opposite allele at
11q markers (PYGM, D11S917, and D11S1339) was
observed in the PDEC component compared with the
adenocarcinoma.
Comparing the genetic similarities among the four
microdissected components from the two tumors of
Patient 1 (Adc, D, MuAdc, and PDEC/WDEC in Table
2) only one common LOH region at 11q22 (D11S927,
D11S2000, and D11S1339) was shared by both the
adenocarcinomas (Adc and MuAdc microspecimens)
together with the high grade dysplasia (D microspeci-
men). On the contrary, the PDEC component from the
mixed tumor showed no common LOH region with the
synchronous adenocarcinoma (Fig. 1). Interestingly, a
strong genetic relationship was observed comparing
the allelotypes of microspecimens D and Adc that
shared an extensive loss of all informative markers on
chromosome 11 and 6q25–6q27 region (Table 2).
Only one collision tumor composed by a WDEC
associated with adenocarcinoma occurred (Case 6),
and completely different allelotypes between the two
components were observed. In particular, whereas the
adenocarcinoma showed LOH at APC and at chromo-
some 17 and 18q markers (TP53, D17S928, D18S474,
and D18S70), the well differentiated endocrine carci-
noma exhibited allelic losses at 3p (D3S1038 and
D3S1581) and at chromosome 11 loci (D11S1318,
D11S917, D11S1339, and D11S1347) (Fig. 2).
Discussion
The microallelotyping analysis of heterogeneous tu-
mors exhibiting the coexistence in the same slide
either of histologically different components or of an
early and more advanced stage of the same neoplasm
represents one of the most successful approaches to
defining the clonality and timing of the genetic events
underlying tumor progression at various sites (Abeln et
Table 3. Clinicopathological Data of Mixed and Collision Endocrine-Exocrine Tumors
Case Age Sex Tumor location Tumor histology p53-IR
Positive immunostainings of the
endocrine components
1 62 M Stomach Composite
MuAdc 
PDEC  Syn, NSE, 5HT, VMAT1
2 37 M Stomach Composite
Adc 
PDEC  Syn, NSE, ChromA
3 52 F Transverse colon Combined
MuAdc Rare cells
WDEC  Syn,, NSE, ChromA, 5HT
4 60 M Descending
colon
Composite
Ad
focalPDEC
 Syn, NSE
5 77 F Transverse colon Combined
Adc 
PDEC  Syn, NSE
6 70 F Rectum Collision
Adc 
WDEC  Syn, NSE, ChromA, PP, glic
IR, immunoreactivity; MuAdc, mucinous adenocarcinoma; PDEC, poorly differentiated endocrine carcinoma; Adc, adenocarcinoma; Ad, adenoma; WDEC,
well-differentiated endocrine carcinoma; syn, synaptophysin; 5HT, serotonin; VMAT1, vesicular monoamine transporter 1; ChromA, Chromogranin A; PP, pancreatic
polypeptide; glic, glicentin; NSE, neuron-specific enolase.
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al, 1995; Boland et al, 1995; Chen et al, 1992; Macin-
tosh et al, 1998; Shen et al, 2000). The strategy used,
which has been successfully applied in defining a
model for colorectal tumorigenesis (Fearon and Vo-
gelstein, 1990), is that a prevalent genetic alteration
that is consistently seen, regardless of the histologic
type, grade, or stage, is considered an early event in
the tumorigenesis and supports the hypothesis of a
monoclonal origin despite the intratumor heterogene-
ity. According to this model, additional genetic alter-
ations restricted to either advanced stages and grades
or to specific histologic types are interpreted as later
events during the progression of the tumor.
Mixed exocrine-endocrine tumors display a high
degree of intratumor heterogeneity in terms of histo-
logic appearance and immunophenotypic features
and do not exhibit easily detectable pathologic tracts
to define a sequential evolution. Therefore, it is not
Figure 1.
Allelotypes at TP53 and D11S2000 loci of the five microspecimens from normal gastric mucosa (A) and the two synchronous gastric tumors (B and D) of Patient
1. The electropherograms in the left panel show an identical allelic loss at TP53 locus (arrows) shared by the high grade dysplasia (E), mucinous adenocarcinoma
(F), poorly differentiated endocrine carcinoma (PDEC) (G), and allelic retention in the synchronous adenocarcinoma (B and C). The electropherograms on the right
panel show an identical allelic loss at D11S2000 locus (arrows) shared by the synchronous adenocarcinoma (B), high grade dysplasia (E), mucinous adenocarcinoma
(F), and allelic retention in PDEC.
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clear if the biphenotypic differentiation represents a
genetic continuum from a common pluripotent stem
cell or if the exocrine and endocrine tumor compo-
nents arise from two distinct precursors through dif-
ferent tumorigenetic pathways (Kim et al, 2002; Peison
and Benisch, 1983; Vortmeyer et al, 1997; Yamashita
and Flinner, 1985).
In this study, a strong genetic relationship between
the exocrine and endocrine components was demon-
strated in all mixed tumors examined (Cases 1 to 5 in
Table 2) regardless of the primary site, type, or grade
of the mixed tumor. Both components of these five
cases exhibited primary common genetic alterations
and secondary alterations restricted to the endocrine
component (Table 2). These results strongly support
the hypothesis of a monoclonal origin of the two
components from a pluripotent epithelial stem cell that
undergoes a biphenotypic differentiation after carci-
nogenesis is initiated. Therefore, the endocrine com-
ponent of a mixed carcinoma with juxtaposed areas of
high grade dysplasia, adenoma, or adenocarcinoma
could represent a differentiation spectrum of the same
tumor. Because the PDECs invariably showed a stron-
ger intratumor homogeneity for LOH than the exocrine
component and additional allelic losses restricted to
PDECs were often observed, it is conceivable that the
endocrine differentiation may be from an exocrine to
an endocrine cell type and not vice versa.
In this scenario, the association of PDEC with
adenoma (Case 4) provides evidence that the differ-
entiation into small cell carcinoma may occur at a
relatively early stage in the gastrointestinal carcino-
genesis. Moreover, these results are in agreement
with the findings reported in two recent microallelo-
typing analyses studying seven mixed colorectal
PDECs and eight mixed gastric PDECs (Kim et al,
2002; Vortmeyer et al, 1997). Interestingly, Vortm-
eyer et al reported the presence of genetic changes
of the adenoma-adenocarcinoma sequence (includ-
ing APC, DCC, and p53 LOH) not only in mixed
PDECs but also in pure PDECs of the colon-rectum,
speculating that both types of tumors share both the
histogenesis and the pathogenetic mechanisms
with the colorectal adenocarcinoma. In our series,
TP53 LOH and/or immunohistochemical p53 protein
accumulation was always found in both compo-
nents of the five mixed tumors examined (Tables 2
and 3). Moreover, considering only the PDEC or
WDEC component, APC LOH was found in all five
mixed tumor and allelic deletion at 18q markers in
two gastric and two colorectal cases. Notwithstand-
ing the small number of cases examined in our
Figure 2.
Allelotypes at TP53 and D11S917 loci of normal tissue (A), WDEC, and adenocarcinoma component (B) from the mixed tumor of Patient 6. In the adenocarcinoma
component, TP53 LOH (arrow) and allelic retention at D11S917 marker are evident. On the contrary the WDEC component shows D11S917 LOH (arrow) and allelic
retention at the TP53 marker.
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study, these findings suggest a recurrent involve-
ment of 5q, 17p, and 18q chromosome arms in all of
the endocrine components analyzed, regardless of
the primary site. In particular, TP53 LOH or mono-
somy of chromosome 17 seems to be the common
feature of all mixed tumors examined, probably
representing a very early genetic event in the devel-
opment of these tumors. It is intriguing to find that
the TP53 gene is directly involved in a molecular
pathway related to cellular responses against
double-strand breaks (DSBs) arisen in DNA (Kanaar
et al, 1998; Venkitaraman, 1999). Given the central
role of DSB-induced chromosome breakage to
cause genomic deletion or nonhomologous recom-
bination (Moynahan and Jasin, 1997; Windle et al,
1991;), it is conceivable that both mixed and pure
endocrine tumor etiology is specifically linked to a
chromosomal instability initiated by DSBs. In agree-
ment with this hypothesis, the allelotypes of the five
mixed tumors examined showed evidence of aneu-
ploidy, because an extensive loss of all informative
markers on particular chromosomal arms (including
6q and 3p) or even of the whole chromosome
(chromosomes 3, 11, and 17) was found (Table 2).
In Patient 1 it was possible to compare the allelo-
types of the mixed PDEC-adenocarcinoma (consider-
ing all of the three microspecimens of high grade
dysplasia, mucinous adenocarcinoma, and PDEC)
and the synchronous adenocarcinoma of the stomach
(Fig. 1). Interestingly, whereas the PDEC component
of the mixed tumor showed no common LOH region
with the synchronous adenocarcinoma, a common
genetic LOH at 11q22 (D11S927, D11S2000, and
D11S1339) was shared by both the adenocarcinomas
(Adc and MuAdc microspecimens) together with the
high grade dysplasia (D microspecimen). The intrigu-
ing aspect is that the microspecimen of the high grade
dysplasia was surrounding the mixed tumor (Fig. 1)
located on the posterior wall of the stomach, and it
was distant from the second adenocarcinoma located
in the angular region of the stomach. The identical
allelotypes at chromosome 11 and 6q26–27 markers
of the high grade dysplasia and the adenocarcinoma
of the angulus suggests that, despite the physical
distance between the two microspecimens, common
genetic alterations present through the gastric mu-
cosa could precede the initiation of both the synchro-
nous tumors. This idea is consistent with the obser-
vation of three small ulcers in both the angular region
and in the posterior wall of the stomach at the time of
the esophagogastroduodenoscopy.
In addition to the results concerning the allelotypes
of the five PDEC/WDEC-adenocarcinoma/adenoma
tumors, this study provides for the first time a molec-
ular support to the identification of collision-type tu-
mors as a rare entity within the spectrum of tumors
formed by an endocrine and an exocrine component.
In particular, we reported two completely different
molecular profiles for the two microspecimens from
the only collision tumor of our series formed by a
WDEC and an adenocarcinoma. In this tumor, the
adenocarcinoma component showed the typical ge-
netic changes of the adenoma-adenocarcinoma se-
quence (such as APC, TP53, and 18q LOH), whereas
the WDEC exhibited allelic losses at chromosome 11
and 3p loci but allelic retention at APC, TP53, and 18q
markers as reported by Vortmeyer et al (Vortmeyer et
al, 1997). These molecular findings, together with the
interesting observation that the endocrine and exo-
crine areas of this tumor gave separate metastases to
different lymph nodes without mixture of the two
components, confirm the existence of double tumors
growing next to each other coincidentally but showing
different histogenesis and different tumorigenetic
pathways.
In conclusion, this work supports the hypothesis
that unlike endocrine-exocrine collision tumors, a
monoclonal mechanism of tumorigenesis is the most
frequent genetic event in mixed endocrine-exocrine
tumors of both composite and combined types and, in
particular, seems to be a peculiar feature of neoplastic
transformation of the mixed tumors with PDECs.
Materials and Methods
Patients and Samples
One collision neoplasm and five mixed endocrine-
exocrine tumors of the gut were selected from the files
of the Department of Pathology of the Varese Univer-
sity Hospital. All tumors were surgically resected and
immediately fixed in buffered formalin (4% [lsqb] w/v
[rsqb] formaldehyde and 0.05 mol/L acetate buffer) for
24 hours, routinely processed and paraffin embedded.
Five-m–thick sections were stained with
hematoxylin-eosin, alcian blue-periodic acid Schiff,
and Grimelius silver impregnation for the histopatho-
logic evaluation. The main clinicopathologic data of
patients are summarized in Table 3. In the five mixed
tumors, the endocrine components consisted of a
pure PDEC (three cases) or WDEC (one case) or a
PDEC with areas of WDEC (one case), which was
associated with adenocarcinoma in four cases (two of
them were mucinous adenocarcinomas) and with a
villous adenoma in one case. The only collision tumor
was located in the rectum and consisted of a well
differentiated malignant endocrine tumor (WDEC) as-
sociated with an adenocarcinoma. In three of the five
mixed tumors, the two components were mainly sep-
arated, although close to each other (composite tu-
mors). In two cases the endocrine and exocrine com-
ponents were mainly intermingled (combined tumor).
One of the two gastric tumors (Case 2) presented
lymph node metastases at the time of surgery. The
other case (Case 1), which was an early gastric cancer
confined to submucosa, was not associated with
metastases. In this case an adenocarcinoma of intes-
tinal type, completely separated from the mixed tu-
mor, was found in the stomach. Among colonic tu-
mors three out of four neoplasms metastasized (Cases
3, 4, and 6) to regional lymph nodes. Interestingly, the
rectal collision neoplasm (WDEC-adenocarcinoma)
showed metastases to regional lymph nodes. The
endocrine and exocrine components gave separate
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metastases to different lymph nodes, and mixed
exocrine-endocrine metastases were not detected.
Immunohistochemistry
Immunohistochemical investigations were performed
in all cases to define the immunophenotype of the
endocrine components employing the antibodies and
antisera (Table 4). Three-m–thick sections were
mounted on poly-L-lysine–coated slides and then
deparaffinized and hydrated through graded alcohols
to water. Endogenous peroxidase activity was re-
moved by dipping sections in 3% hydrogen peroxide
for 10 minutes at room temperature. Thereafter, sec-
tions were incubated with specific antibodies (Table 4)
for 18 to 20 hours at 4° C. Then the avidin-biotin-
peroxidase procedure was performed according to
Hsu et al (1981). The peroxidase activity, indicating the
presence of the antigen that we were looking for, was
finally revealed by 0.03% 3,3' diaminobenzidine, and
nuclei were counterstained with Harris hematoxylin.
Sections immunostained for glucagon-glicentin and
somatostatin were pretreated with 0.003% subtilisin
(protease type XXVII or Nagarse protease; Sigma, St
Louis, Missouri) in 0.05 M Tris-buffered saline 7.4 pH
at room temperature for 10 minutes. Sections immu-
nostained for VMAT2 were pretreated with 0.05%
trypsin (Sigma) in 0.05 M Tris-buffered saline 7.4 pH at
37° C for 20 minutes, while sections immunostained
for synaptophysin, NSE, chromogranin A, and p53
were pretreated with citrate buffer 6 pH in a micro-
wave oven at 700 W for 10 minutes. Specificity con-
trols consisted of absorption of each antibody with 10
to 20 nMol of related antigen, substitution of the
primary antibody with nonimmune serum of the same
species at the same dilution, and the use of control
tissues with or without the pertinent antigens.
Microdissection and DNA Extraction
Five-m-thick histologic sections of tumor tissues
were obtained from paraffin blocks and stained with
hematoxylin-eosin. Using these slides as a guide,
microspecimens of the exocrine and the endocrine
tumors were carefully scraped with a fine scalpel
blade from serial unstained sections from the same
paraffin blocks. Homogeneous portions of tumor com-
ponents were selected to obtain  80% purity in each
cell population. Control tissue for analysis of constitu-
tional DNA included normal mucosa or lymph node
tissue. DNA extraction from microdissected cells was
performed as previously described (Furlan et al, 2002).
Allelotyping PCR
Normal and tumor DNA samples were allelotyped for
35 polymorphic microsatellite markers covering a total
of six chromosomes, including 3, 5q, 6, 11, 17, and 18
(Table 3). The markers were selected from the Ge-
nome database (www.gdb.org) and from the physical
map of the International RH Mapping Consortium
(www.ncbi.nlm.nih.gov/genemap99) on the basis of
chromosomal location and heterozygosity. Forward
primers were synthesized with a fluorescent tag (FAM,
HEX, or TET) on the 5' end and purified using standard
HPLC. Fifty ng of DNA was amplified in a 15-l
reaction solution containing 1.5 l of 10 buffer
(Roche, Mannheim, Germany), 1.25 to 2.25 mM MgCl2,
0.3 M primer pairs, 200 M dNTPs, and 2U DNA
polymerase (Roche). Amplifications were performed
using a 5-minute initial denaturation at 95° C, followed
by 10 cycles of 50 seconds at 94° C, 50 seconds at
55° C, and 50 seconds at 72° C; and by 25 cycles of
30 seconds at 89° C, 30 seconds at 55° C, and 30
seconds at 72° C. The fluorescently labeled PCR
products were subjected to electrophoresis on an
Applied Biosystems 310 automated DNA sequencer
(Applied Biosystems, Milan, Italy), and the fluorescent
signals from the different sized alleles were recorded
and analyzed using Genescan software (version 2.1)
(Applied Biosystems).
Definition of Allelic Loss
An imbalance factor was defined as the ratio of relative
allelic peak height in the tumor DNA to relative allelic
Table 4. Antibodies and Antisera Used in Immunohistochemical Analyses
Antibodies/antisera P/M (clone) Dilution Source
Synaptophysin (Syn) M (SY38) 1:100 BioGenex, San Ramon, California
Neuron specific enolase (NSE) M (H14) 1:100 Dako, Copenhagen, Denmark
Chromogranin A (ChromA) M (PHE5) 1:50 Enzo Diagnostics, Farmingdale, New York
Glicentin-glucagon (Glic) P 1:2500 Milab, Malmo, Sweden
Pancreatic polypeptide (PP) P 1:4000 Cambridge Research Biochemicals, Cambridge,
United Kingdom
Somatostatin (Som) M (YC7) 1:10 Immunochimica Labometrics, Milan, Italy
Serotonin (5HT) M (YC5) 1:50 Biogenesis, Bournemouth, United Kingdom
C-terminus gastrin-CCK-cerulein M (B4) 1:10000 Farmitalia, Milan, Italy
Vesicular monoamine transporter 1 (VMAT1) P 1:2000 Fisher Advanced Immunohistochemicals, Trevose,
Pennsylvania
Vesicular monoamine transporter 2 (VMAT2) P 1:500 Chemicon International, Temecula, California
p53 M (D0-7) 1:1000 Dako, Copenhagen, Denmark
P/M, polyclonal/monoclonal.
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peak height in the corresponding normal DNA. The
formula employed for the calculation was T2: T1/N2:
N1, where T1 and N1 are the height values for the
smaller allele and T2 and N2 are the height values for
the larger allele of the tumor and normal samples,
respectively. For informative markers LOH was scored
when signal reduction for one allele was of 50% or
more (allelic imbalance factor  0.5 or  2).
Random preferential allele amplification was some-
times seen, resulting in artifactual allelic imbalances in
the PCR products. This was seen when using DNA
from archival sections as opposed to purified high–
molecular-weight DNA. However, this artifact could be
distinguished from true allelic losses by repeating the
experiments several times (at least three times). Allelic
losses were assigned only after the experiments were
repeated at least three times and if the losses were
found consistently in all repeated experiments.
Evaluation of Intratumor Heterogeneity for LOH
Because pure tumor-cell contents were used in this
analysis by microdissection, we carefully evaluated
the degree of allelic signal reduction at all markers in
which LOH was scored to assess the presence of an
intratumor heterogeneity rather than an intratumor
homogeneity for LOH.
A condition of genetic homogeneity was defined
when a tumor DNA showed LOH with at least 80% of
allelic signal reduction compared with normal DNA.
On the contrary the presence of an intratumor genetic
heterogeneity was assessed when we observed LOH
at one locus with an allelic signal reduction ranging
from 50% to 80% compared with normal DNA. More-
over, a condition of borderline allelic imbalance (with
an allelic signal reduction ranging from 40% to 50%)
was thoroughly considered in the analysis of high
grade dysplasia samples because of the well known
clonal heterogeneity reported in this preneoplastic
lesion (Boland et al, 1995).
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